Items Tagged ‘FoundationFocus™ CDxBRCA’

December 20, 2016

Rubraca™ Is Granted Accelerated Approval for Advanced Ovarian Cancer


The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rubraca™ (rucaparib) for the treatment of women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a BRCA gene mutation. Each year in the U.S. roughly 22,000 women are diagnosed with ovarian cancer and more […]

View full entry

Tags: fda, FoundationFocus™ CDxBRCA, News, Ovarian Cancer, Ovarian cancer BRCA mutation, Rubraca, Rucaparib, Stage II-IV Ovarian Cancer